CN110812322A - Preparation method of hydrogel for targeted therapy of cancer cells - Google Patents

Preparation method of hydrogel for targeted therapy of cancer cells Download PDF

Info

Publication number
CN110812322A
CN110812322A CN201911068607.2A CN201911068607A CN110812322A CN 110812322 A CN110812322 A CN 110812322A CN 201911068607 A CN201911068607 A CN 201911068607A CN 110812322 A CN110812322 A CN 110812322A
Authority
CN
China
Prior art keywords
hydrogel
cancer cells
acrylic acid
magnetic nanoparticles
targeted therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201911068607.2A
Other languages
Chinese (zh)
Inventor
喻四海
赵娇娇
施法宽
张世友
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KUNSHAN BYE MACROMOLECULE MATERIAL CO Ltd
Original Assignee
KUNSHAN BYE MACROMOLECULE MATERIAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KUNSHAN BYE MACROMOLECULE MATERIAL CO Ltd filed Critical KUNSHAN BYE MACROMOLECULE MATERIAL CO Ltd
Priority to CN201911068607.2A priority Critical patent/CN110812322A/en
Publication of CN110812322A publication Critical patent/CN110812322A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1803—Semi-solid preparations, e.g. ointments, gels, hydrogels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/008—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Materials Engineering (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

The invention belongs to the technical field of hydrogel preparation, and particularly discloses a preparation method of hydrogel for targeted therapy of cancer cells, which comprises the following steps: mixing acrylic acid and Fe3O4 magnetic nanoparticles in a molar ratio of 1:1 in a mixing device, reacting for 10-15min at 35-42 ℃ in a reactor to combine the acrylic acid and the Fe3O4 magnetic nanoparticles to obtain composite hydrogel, and finally wrapping anticancer drug adriamycin in the composite hydrogel obtained in the step S2; the invention adopts magnetic nanoparticles for drug carriers and disease diagnosis and treatment, acrylic acid and Fe3O4 magnetic nanoparticles are combined to form composite hydrogel, and anticancer drug adriamycin is wrapped in the composite hydrogel, the hydrogel can be rapidly released to achieve the effect of targeted therapy of cancer cells, and the nano Fe3O4 magnetic material as the targeted drug carrier can be combined with drug molecules on one hand and can also protect the drug molecules on the other hand.

Description

Preparation method of hydrogel for targeted therapy of cancer cells
Technical Field
The invention belongs to the technical field of hydrogel preparation, and particularly relates to a preparation method of hydrogel for targeted therapy of cancer cells.
Background
At present, cancer is clinically treated mainly by a combination therapy of western medicine operations, radiotherapy and chemotherapy and traditional Chinese medicines, but as the target selectivity of an anti-tumor medicine and a therapy is not high, the anti-tumor medicine and the therapy can kill tumor cells and generate larger toxic and side effects or damage to normal tissues, meanwhile, the tumor cells can easily generate multi-medicine resistance to the chemotherapeutic medicine to trigger autoimmune reaction to remove the medicine or block the medicine from playing the effect, the magnetic nanoparticles develop rapidly and are widely applied to the aspects of biological marking and separation, Magnetic Resonance Imaging (MRI), tissue repair, medicine carriers and disease diagnosis and treatment, the magnetic nano Fe3O4 particles are simple to manufacture, crystals are nontoxic to cells, and are minerals with the strongest magnetism in the nature, can meet many requirements on biomedicine, and are widely applied to the field of biomedicine by scientists.
With the increasing perfection of a drug release system, the design and synthesis of a targeted drug carrier play a crucial role in medicine and medical care, and meanwhile, the innovation of a targeted drug carrier material and a nanotechnology jointly promote the progress of a drug delivery system, so that the construction of the targeted drug carrier is of great significance in improving the high targeting selectivity of an anticancer drug on cancer cells and enhancing the controlled release capacity of the drug to achieve the purpose of long-acting tumor inhibition.
Disclosure of Invention
The present invention aims to provide a method for preparing hydrogel for targeted therapy of cancer cells, so as to solve the problems in the background art.
In order to achieve the purpose, the invention adopts the following technical scheme: a method of preparing a hydrogel for targeted therapy of cancer cells, comprising the steps of:
s1, mixing acrylic acid and Fe3O4 magnetic nanoparticles in a molar ratio of 1:1 in a mixing device;
s2, then reacting for 10-15min at 35-42 ℃ in a reactor to combine acrylic acid with Fe3O4 magnetic nanoparticles to obtain composite hydrogel;
s3, finally, wrapping the anticancer drug adriamycin in the composite hydrogel obtained in the S2 step;
s4, completing the preparation of the hydrogel for targeted therapy of cancer cells.
Preferably, the acrylic acid combined with the Fe3O4 magnetic nanoparticles in step S2 to obtain the composite hydrogel, which can be rapidly released to achieve the effect of targeted therapy of cancer cells.
Preferably, the nano Fe3O4 magnetic material is used as a targeting drug carrier, so that the targeting drug carrier can be combined with drug molecules on one hand, and can also protect the drug molecules on the other hand.
Preferably, the mixing apparatus in step S1 is the same as the reactor in step S2.
Preferably, the reaction temperature in step S2 is 40 ℃.
Preferably, the reaction time in step S2 is 12 min.
Preferably, after the anticancer drug doxorubicin is added to the composite hydrogel in the step S3 for 30min to 60min, the absorbance of the released anticancer drug doxorubicin is measured by using an ultraviolet-visible spectrophotometer, and then the concentration of the released anticancer drug doxorubicin is obtained.
The invention has the technical effects and advantages that: compared with the prior art, the magnetic nano-particles of the invention have rapid development and are widely applied to the aspects of biological labeling and separation, Magnetic Resonance Imaging (MRI), tissue repair, drug carriers and disease diagnosis and treatment, the magnetic nano Fe3O4 particles are simple to manufacture, crystals are nontoxic to cells, and are minerals with the strongest magnetism in the nature, and can meet a plurality of requirements on biomedicine, scientists can widely apply the magnetic nano-particles to the field of biomedicine, acrylic acid and Fe3O4 magnetic nano-particles are combined to form composite hydrogel, and anticancer drug adriamycin is wrapped in the composite hydrogel, the hydrogel can be rapidly released to achieve the effect of targeted therapy of cancer cells, and the nano Fe3O4 magnetic material as a targeted drug carrier can be combined with drug molecules on one hand, and can also protect the drug molecules on the other hand.
Detailed Description
The technical solutions in the embodiments of the present invention are clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. The specific embodiments described herein are merely illustrative of the invention and do not delimit the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
The invention provides a preparation method of hydrogel for targeted therapy of cancer cells, which comprises the following steps:
s1, mixing acrylic acid and Fe3O4 magnetic nanoparticles in a molar ratio of 1:1 in a mixing device;
s2, then reacting for 10min at 35 ℃ in a reactor to combine acrylic acid with Fe3O4 magnetic nanoparticles to obtain composite hydrogel;
s3, finally, wrapping the anticancer drug adriamycin in the composite hydrogel obtained in the S2 step;
s4, completing the preparation of the hydrogel for targeted therapy of cancer cells.
Specifically, in step S2, the acrylic acid and the Fe3O4 magnetic nanoparticles are combined to obtain a composite hydrogel, which can be rapidly released to achieve the effect of targeted therapy of cancer cells.
Specifically, the nano Fe3O4 magnetic material is used as a targeting drug carrier, so that the drug molecule can be combined on one hand, and the drug molecule can be protected on the other hand.
Specifically, the mixing apparatus in step S1 is the same as the reactor in step S2.
Specifically, after the anticancer drug doxorubicin is added to the composite hydrogel in step S3 for 30min, the absorbance of the released anticancer drug doxorubicin is measured by an ultraviolet-visible spectrophotometer, and the concentration of the released anticancer drug doxorubicin is obtained.
According to the embodiment, acrylic acid and Fe3O4 magnetic nanoparticles are mixed in a mixing device according to the molar ratio of 1:1, then the mixture is reacted for 10min at 35 ℃ in a reactor, so that the acrylic acid and the Fe3O4 magnetic nanoparticles are combined to obtain composite hydrogel, and finally anticancer drug adriamycin is wrapped in the composite hydrogel obtained in the step S2, so that the preparation of the hydrogel for targeted therapy of cancer cells is completed.
Example 2
The invention provides a preparation method of hydrogel for targeted therapy of cancer cells, which comprises the following steps:
s1, mixing acrylic acid and Fe3O4 magnetic nanoparticles in a molar ratio of 1:1 in a mixing device;
s2, then reacting for 11min at 37 ℃ in a reactor to combine acrylic acid with Fe3O4 magnetic nanoparticles to obtain composite hydrogel;
s3, finally, wrapping the anticancer drug adriamycin in the composite hydrogel obtained in the S2 step;
s4, completing the preparation of the hydrogel for targeted therapy of cancer cells.
Specifically, in step S2, the acrylic acid and the Fe3O4 magnetic nanoparticles are combined to obtain a composite hydrogel, which can be rapidly released to achieve the effect of targeted therapy of cancer cells.
Specifically, the nano Fe3O4 magnetic material is used as a targeting drug carrier, so that the drug molecule can be combined on one hand, and the drug molecule can be protected on the other hand.
Specifically, the mixing apparatus in step S1 is the same as the reactor in step S2.
Specifically, after the anticancer drug doxorubicin is added to the composite hydrogel in step S3 for 40min, the absorbance of the released anticancer drug doxorubicin is measured by an ultraviolet-visible spectrophotometer, and the concentration of the released anticancer drug doxorubicin is obtained.
According to the embodiment, acrylic acid and Fe3O4 magnetic nanoparticles are mixed in a mixing device according to the molar ratio of 1:1, then the mixture is reacted for 11min at 37 ℃ in a reactor, so that the acrylic acid and the Fe3O4 magnetic nanoparticles are combined to obtain composite hydrogel, and finally anticancer drug adriamycin is wrapped in the composite hydrogel obtained in the step S2, so that the preparation of the hydrogel for targeted therapy of cancer cells is completed.
Example 3
The invention provides a preparation method of hydrogel for targeted therapy of cancer cells, which comprises the following steps:
s1, mixing acrylic acid and Fe3O4 magnetic nanoparticles in a molar ratio of 1:1 in a mixing device;
s2, then reacting for 12min at 39 ℃ in a reactor to combine acrylic acid with Fe3O4 magnetic nanoparticles to obtain composite hydrogel;
s3, finally, wrapping the anticancer drug adriamycin in the composite hydrogel obtained in the S2 step;
s4, completing the preparation of the hydrogel for targeted therapy of cancer cells.
Specifically, in step S2, the acrylic acid and the Fe3O4 magnetic nanoparticles are combined to obtain a composite hydrogel, which can be rapidly released to achieve the effect of targeted therapy of cancer cells.
Specifically, the nano Fe3O4 magnetic material is used as a targeting drug carrier, so that the drug molecule can be combined on one hand, and the drug molecule can be protected on the other hand.
Specifically, the mixing apparatus in step S1 is the same as the reactor in step S2.
Specifically, after the anticancer drug doxorubicin is added to the composite hydrogel in step S3 for 50min, the absorbance of the released anticancer drug doxorubicin is measured by an ultraviolet-visible spectrophotometer, and the concentration of the released anticancer drug doxorubicin is obtained.
According to the embodiment, acrylic acid and Fe3O4 magnetic nanoparticles are mixed in a mixing device according to the molar ratio of 1:1, then the mixture is reacted for 12min at 39 ℃ in a reactor, so that the acrylic acid and the Fe3O4 magnetic nanoparticles are combined to obtain composite hydrogel, and finally anticancer drug adriamycin is wrapped in the composite hydrogel obtained in the step S2, so that the preparation of the hydrogel for targeted therapy of cancer cells is completed.
Example 4
The invention provides a preparation method of hydrogel for targeted therapy of cancer cells, which comprises the following steps:
s1, mixing acrylic acid and Fe3O4 magnetic nanoparticles in a molar ratio of 1:1 in a mixing device;
s2, then reacting for 13min at 40 ℃ in a reactor to combine acrylic acid with Fe3O4 magnetic nanoparticles to obtain composite hydrogel;
s3, finally, wrapping the anticancer drug adriamycin in the composite hydrogel obtained in the S2 step;
s4, completing the preparation of the hydrogel for targeted therapy of cancer cells.
Specifically, in step S2, the acrylic acid and the Fe3O4 magnetic nanoparticles are combined to obtain a composite hydrogel, which can be rapidly released to achieve the effect of targeted therapy of cancer cells.
Specifically, the nano Fe3O4 magnetic material is used as a targeting drug carrier, so that the drug molecule can be combined on one hand, and the drug molecule can be protected on the other hand.
Specifically, the mixing apparatus in step S1 is the same as the reactor in step S2.
Specifically, after the anticancer drug doxorubicin is added to the composite hydrogel in step S3 for 50min, the absorbance of the released anticancer drug doxorubicin is measured by an ultraviolet-visible spectrophotometer, and the concentration of the released anticancer drug doxorubicin is obtained.
According to the embodiment, acrylic acid and Fe3O4 magnetic nanoparticles are mixed in a mixing device according to the molar ratio of 1:1, then the mixture is reacted for 13min at 40 ℃ in a reactor, so that the acrylic acid and the Fe3O4 magnetic nanoparticles are combined to obtain composite hydrogel, and finally anticancer drug adriamycin is wrapped in the composite hydrogel obtained in the step S2, so that the preparation of the hydrogel for targeted therapy of cancer cells is completed.
Example 5
The invention provides a preparation method of hydrogel for targeted therapy of cancer cells, which comprises the following steps:
s1, mixing acrylic acid and Fe3O4 magnetic nanoparticles in a molar ratio of 1:1 in a mixing device;
s2, then reacting for 15min at 42 ℃ in a reactor to combine acrylic acid with Fe3O4 magnetic nanoparticles to obtain composite hydrogel;
s3, finally, wrapping the anticancer drug adriamycin in the composite hydrogel obtained in the S2 step;
s4, completing the preparation of the hydrogel for targeted therapy of cancer cells.
Specifically, in step S2, the acrylic acid and the Fe3O4 magnetic nanoparticles are combined to obtain a composite hydrogel, which can be rapidly released to achieve the effect of targeted therapy of cancer cells.
Specifically, the nano Fe3O4 magnetic material is used as a targeting drug carrier, so that the drug molecule can be combined on one hand, and the drug molecule can be protected on the other hand.
Specifically, the mixing apparatus in step S1 is the same as the reactor in step S2.
Specifically, after the anticancer drug doxorubicin is added to the composite hydrogel in step S3 for 60min, the absorbance of the released anticancer drug doxorubicin is measured by an ultraviolet-visible spectrophotometer, and the concentration of the released anticancer drug doxorubicin is obtained.
According to the embodiment, acrylic acid and Fe3O4 magnetic nanoparticles are mixed in a mixing device according to the molar ratio of 1:1, then the mixture is reacted for 15min at 42 ℃ in a reactor, so that the acrylic acid and the Fe3O4 magnetic nanoparticles are combined to obtain composite hydrogel, and finally anticancer drug adriamycin is wrapped in the composite hydrogel obtained in the step S2, so that the preparation of the hydrogel for targeted therapy of cancer cells is completed.
Finally, it should be noted that: although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that modifications may be made to the embodiments or portions thereof without departing from the spirit and scope of the invention.

Claims (7)

1. A method for preparing hydrogel for targeted therapy of cancer cells, which is characterized by comprising the following steps: the method comprises the following steps:
s1, mixing acrylic acid and Fe3O4 magnetic nanoparticles in a molar ratio of 1:1 in a mixing device;
s2, then reacting for 10-15min at 35-42 ℃ in a reactor to combine acrylic acid with Fe3O4 magnetic nanoparticles to obtain composite hydrogel;
s3, finally, wrapping the anticancer drug adriamycin in the composite hydrogel obtained in the S2 step;
s4, completing the preparation of the hydrogel for targeted therapy of cancer cells.
2. The method of claim 1, wherein the hydrogel is prepared by a method comprising the steps of: in step S2, the composite hydrogel obtained by combining acrylic acid and the Fe3O4 magnetic nanoparticles can be rapidly released to achieve the effect of targeted therapy of cancer cells.
3. The method of claim 1, wherein the hydrogel is prepared by a method comprising the steps of: the nano Fe3O4 magnetic material is used as a targeting drug carrier, so that the drug molecule can be combined on one hand, and the drug molecule can be protected on the other hand.
4. The method of claim 1, wherein the hydrogel is prepared by a method comprising the steps of: the mixing apparatus in step S1 was the same as the reactor in step S2.
5. The method of claim 1, wherein the hydrogel is prepared by a method comprising the steps of: the reaction temperature in step S2 was 40 ℃.
6. The method of claim 1, wherein the hydrogel is prepared by a method comprising the steps of: the reaction time in step S2 was 12 min.
7. The method of claim 1, wherein the hydrogel is prepared by a method comprising the steps of: and (4) after adding the anticancer drug adriamycin into the composite hydrogel in the step S3 for 30min to 60min, measuring the absorbance of the released anticancer drug adriamycin by using an ultraviolet-visible spectrophotometer, and further obtaining the concentration of the released anticancer drug adriamycin.
CN201911068607.2A 2019-11-05 2019-11-05 Preparation method of hydrogel for targeted therapy of cancer cells Pending CN110812322A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911068607.2A CN110812322A (en) 2019-11-05 2019-11-05 Preparation method of hydrogel for targeted therapy of cancer cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911068607.2A CN110812322A (en) 2019-11-05 2019-11-05 Preparation method of hydrogel for targeted therapy of cancer cells

Publications (1)

Publication Number Publication Date
CN110812322A true CN110812322A (en) 2020-02-21

Family

ID=69552841

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911068607.2A Pending CN110812322A (en) 2019-11-05 2019-11-05 Preparation method of hydrogel for targeted therapy of cancer cells

Country Status (1)

Country Link
CN (1) CN110812322A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112755186A (en) * 2021-01-11 2021-05-07 南京邮电大学 Composite nano drug-loading system and preparation method thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112755186A (en) * 2021-01-11 2021-05-07 南京邮电大学 Composite nano drug-loading system and preparation method thereof
CN112755186B (en) * 2021-01-11 2022-12-06 南京邮电大学 Composite nano drug-loading system and preparation method thereof

Similar Documents

Publication Publication Date Title
Zhang et al. Positive feedback nanoamplifier responded to tumor microenvironments for self-enhanced tumor imaging and therapy
Ding et al. Chitosan oligosaccharide decorated liposomes combined with TH302 for photodynamic therapy in triple negative breast cancer
CN103705940A (en) Preparation and anti-tumor application of natural active drug-polysaccharide targeted compound
CN105214098A (en) Containing the pharmaceutical carrier and its preparation method and application of polyamino acid and polyphosphoric acid choline
CN102895665B (en) Preparation method of targeting graphene nano-grade drug carrier
CN108559091A (en) Polymer drug carrier, carrier micelle with aggregation-induced emission and doubling sensitivity and preparation method thereof
Zhou et al. Nitric oxide-mediated regulation of mitochondrial protective autophagy for enhanced chemodynamic therapy based on mesoporous Mo-doped Cu9S5 nanozymes
CN109999197B (en) Tumor-targeted nano-composite, preparation method and application thereof in precise sonodynamic-mediated tumor treatment
Zheng et al. Self-polymerized polydopamine-based nanoparticles for acute kidney injury treatment through inhibiting oxidative damages and inflammatory
CN111053911A (en) Reduction response type cross-linking agent and preparation and application of cross-linked hydroxyl drug molecule thereof
Yang et al. Ferrocene-based multifunctional nanoparticles for combined chemo/chemodynamic/photothermal therapy
Zhang et al. Lactate-driving Pt nanoflower with positive chemotaxis for deep intratumoral penetration
CN106421801B (en) A kind of RES macrophage blocking material, tumour multistep therapeutics series medicine and its application
CN110812322A (en) Preparation method of hydrogel for targeted therapy of cancer cells
Wu et al. Multifunctional Protein Hybrid Nanoplatform for Synergetic Photodynamic‐Chemotherapy of Malignant Carcinoma by Homologous Targeting Combined with Oxygen Transport
CN108853512A (en) The preparation and antitumor application thereof of double Types of Medicine cis-platinum/adriamycin-poly-dopamine prodrug nanoparticles
Zhang et al. Chitosan-lactobionic acid-thioctic acid-modified hollow mesoporous silica composite loaded with carborane for boron neutron capture therapy of hepatocellular carcinoma
CN110491455A (en) Kukoamine B application in preparation of anti-tumor drugs
Li et al. Biodegradable covalent organic frameworks achieving tumor micro-environment responsive drug release and antitumor treatment
CN104761732B (en) A kind of nanogel of tumour cell targeting and preparation method thereof and a kind of nanogel of tumour cell targeting carry medicine particle
Lan et al. In vivo investigation of boron-rich nanodrugs for treating triple-negative breast cancers via boron neutron capture therapy
CN107224586B (en) Multifunctional drug carrier with controllable drug loading capacity and application thereof
CN103656670B (en) Glucan-adriamycin conjugate drug and preparation method thereof
CN104817688B (en) A kind of reversible nanogel of surface charge and preparation method thereof and a kind of reversible nanogel medicine carrying granule of surface charge
CN113384698B (en) Self-assembled nano-medicament for synergetic chemotherapy/acousto-photodynamic therapy and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200221

WD01 Invention patent application deemed withdrawn after publication